Special Issue

Development of Vaccines Based on Virus-Like Particles

Message from the Guest Editors

Basic studies on virus structure and assembly have led to the experimental observation that many viral structural proteins have the intrinsic ability to self-assemble into virus-like particles (VLPs). These VLPs have led to better immunological mimics of whole-virus particles compared to soluble capsid subunits, resulting in the improved effectiveness of vaccines and leading to a renaissance in vaccine development. VLP-based vaccines combine many of the advantages of whole-virus-based and recombinant subunit vaccines, exhibiting a high safety profile. VLPs produced using recombinant protein expression systems can stimulate strong B- and T-cell immune responses and have been shown to exhibit self-adjuvanting abilities. In addition, VLPs can be used as platforms for the multimeric display of foreign antigens of interest derived from viruses or other pathogens (chimeric VLPs). This Special Issue aims to collect recent research work on the design, generation and use of VLPs and chimeric VLPs for the development of both human and veterinary new generation vaccines.

Guest Editors

Dr. Esther Blanco

Center for Animal Health Research (CISA-INIA), Valdeolmos, 28130 Madrid, Spain

Dr. Juan Bárcena

Center for Animal Health Research (CISA-INIA), Valdeolmos, 28130 Madrid, Spain

Deadline for manuscript submissions

closed (31 December 2021)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/49897

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI